What's Hot & What's Not in Antibody-Drug Conjugates (ADC) Licensing
What's Hot & What's Not in Antibody-Drug Conjugates (ADC) Licensing
Antibody-Drug Conjugates combine the specificity of the antibody recognizing the antigen target with the potent tumor-killing effects of a cytotoxic, attached typically via a linker. 6 ADCs have already been approved; sales are expected to be about $2b in 2018, growing to $12b by 2024 (GlobalData). Currently, about 100 ADCs are in clinical development.
This whitepaper addressed the following questions, among others:
- What targets are suitable?
- What are the trends in linkers and the drugs to be attached to the antibodies? What are the indications being pursued?
- How are companies dealing with the complexities of internalization and high cost of goods? What kind of data will drive an ADC licensing deal?
- How do the ADCs fit in the world of immuno-oncology?
- What is the future for ADCs?
The virtual discussion was moderated by biopharma partnering expert, Linda Pullan, PhD, of Pullan Consulting along with Jeff Bockman, PhD, the EVP and Head of the Oncology Practice for Cello Health BioConsulting, formerly Defined Health. The panel featured ADC experts who provided unique insight and a look into the challenges and future of ADCs.
White Paper
Contributors:

Linda Pullan, PhD
Pullan Consulting
Linda
and her team at Pullan Consulting offer biotech and pharmaceutical
companies consulting in all aspects of partnering. Linda has a PhD in Biochemistry, a BS in Chemistry, and over twenty years of drug industry experience, including work on more than 75 deals.
Learn More

Jeff Bockman, PhD
EVP & Head of Oncology Practice, Cello Health BioConsulting, formerly Defined Health
Jeff leads the Oncology and Virology Practices at Cello Health BioConsulting, formerly Defined Health. He received a BA from University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University.
Learn More

Peter Dragovich, PhD
Staff Scientist, Genentech
Peter Dragovich received a BS in chemistry from UC Berkeley and subsequently obtained a PhD in synthetic organic chemistry from Caltech under the direction of Professor Andrew Myers. He has worked in the pharmaceutical industry for more than 25 years in both large-pharma and biotech organizations and has performed a variety of research and management activities during that time. He contributed to the discovery and development of several antiviral agents that progressed to human clinical testing including the rhinovirus protease inhibitors Rupintrivir (AG-7088) and AG-7404 as well as the HCV polymerase inhibitors Filibuvir (PF-00868554) and Setrobuvir (ANA-598). He joined Genentech in 2010 and has since worked on multiple projects in both the immunology and oncology therapeutic areas. His Genentech activities include leading the company’s efforts to identify novel payloads and linkers that can be utilized for the creation of new antibody-drug conjugates. His current research interests entail the targeted delivery of novel cargos via antibody-mediated technologies.

Neela Patel, PhD
Executive Director of Business Development, Seattle Genetics
Neela Patel joined Seattle Genetics as Executive Director of Business Development in May 2016, with responsibility for identification, evaluation, and transaction of collaboration, licensing, and acquisition opportunities to diversify the pipeline. Previously, at AbbVie she identified, introduced, and led technical diligence, resulting in more than twenty-five executed deals including collaborations, licensing, and participation in consortia. Dr. Patel spent the first 16 years of her career in drug discovery management positions of increasing responsibility to advance small molecules and biologics from early stage discovery through IND filing at Poniard Pharmaceuticals, Genentech, SUGEN/Pharmacia, and Roche Bioscience.

Jason Kim
President & COO, Molecular Templates
Jason Kim joined Molecular Templates in 2010 and serves as President and Chief Operating Officer. He has 16 years of experience in the biotechnology industry including operations, business development, and venture capital. He previously led corporate development and strategic planning initiatives at OSI Pharmaceuticals and ImClone Systems. He served as an investment professional at Domain Associates where he focused on venture and public investments in biotechnology. Mr. Kim holds an MBA from The Wharton School and a BA in Neuroscience from Wesleyan University.
our sponsors:



